These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 15359845)

  • 1. [Host factors determining the outcome of IFN treatment for chronic hepatitis C].
    Kiyosawa K
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):481-4. PubMed ID: 15359845
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term monitoring of platelet count, as a non-invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy.
    Taniguchi H; Iwasaki Y; Fujiwara A; Sakaguchi K; Moriya A; Yu PC; Takaki A; Fujioka S; Shimomura H; Shiratori Y
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):281-7. PubMed ID: 16460487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.
    Bressler BL; Guindi M; Tomlinson G; Heathcote J
    Hepatology; 2003 Sep; 38(3):639-44. PubMed ID: 12939590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C.
    Promrat K; McDermott DH; Gonzalez CM; Kleiner DE; Koziol DE; Lessie M; Merrell M; Soza A; Heller T; Ghany M; Park Y; Alter HJ; Hoofnagle JH; Murphy PM; Liang TJ
    Gastroenterology; 2003 Feb; 124(2):352-60. PubMed ID: 12557141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon.
    Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
    J Gastroenterol; 2005 Feb; 40(2):148-56. PubMed ID: 15770398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A possible role of human leukocyte antigen(HLA) typing for predicting response to interferon therapy in chronic hepatitis C].
    Korenaga M; Hino K; Okita K
    Nihon Rinsho; 2001 Jul; 59(7):1345-50. PubMed ID: 11494549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Type I IFN receptor].
    Hino K; Yamaguchi Y; Okita K
    Nihon Rinsho; 2001 Jul; 59(7):1351-5. PubMed ID: 11494550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APRI-M6 for predicting long-term outcome of chronic hepatitis C patients after interferon-based therapy: more questions than answers.
    Su TH; Kao JH; Chen DS
    Hepatology; 2007 Jun; 45(6):1586-7; author reply 1587-8. PubMed ID: 17538939
    [No Abstract]   [Full Text] [Related]  

  • 9. Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C.
    Asselah T; Bièche I; Paradis V; Bedossa P; Vidaud M; Marcellin P
    Semin Liver Dis; 2007 Feb; 27(1):13-27. PubMed ID: 17295174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis.
    Loguercio C; Federico A; Masarone M; Torella R; Blanco Cdel V; Persico M
    Am J Gastroenterol; 2008 Dec; 103(12):3159-66. PubMed ID: 18786125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C.
    Romero-Gómez M; González-Escribano MF; Torres B; Barroso N; Montes-Cano MA; Sánchez-Muñoz D; Núñez-Roldan A; Aguilar-Reina J
    Am J Gastroenterol; 2003 Jul; 98(7):1621-6. PubMed ID: 12873589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Necessities of interferon therapy in elderly patients with chronic hepatitis C.
    Ikeda K; Arase Y; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Kumada H
    Am J Med; 2009 May; 122(5):479-86. PubMed ID: 19375558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: predicting response in hepatitis C virus therapy.
    Mihm U; Herrmann E; Sarrazin C; Zeuzem S
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1043-54. PubMed ID: 16611264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of host insulin resistance on fibrosis and response to interferon in chronic hepatitis C.
    Moţa M; Popa S; Mota E; Diaconescu I; Gheorghiţoiu I; Panduru M
    Rom J Intern Med; 2008; 46(2):105-12. PubMed ID: 19284081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chronic hepatitis C with normal level of alanine-aminotransferase].
    Rossi G
    Recenti Prog Med; 2004 Nov; 95(11):509-11. PubMed ID: 15598087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders.
    Imai Y; Tamura S; Tanaka H; Hiramatsu N; Kiso S; Doi Y; Inada M; Nagase T; Kitada T; Imanaka K; Fukuda K; Takehara T; Kasahara A; Hayashi N
    J Viral Hepat; 2010 Mar; 17(3):185-91. PubMed ID: 19709362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients.
    Wada M; Marusawa H; Yamada R; Nasu A; Osaki Y; Kudo M; Nabeshima M; Fukuda Y; Chiba T; Matsuda F
    J Viral Hepat; 2009 Jun; 16(6):388-96. PubMed ID: 19200137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy forecast on interferon in the treatment of chronic viral hepatitis].
    Mei YY; Gao ZL
    Zhonghua Gan Zang Bing Za Zhi; 2011 Jan; 19(1):8-9. PubMed ID: 21272450
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
    Di Bisceglie AM; Thompson J; Smith-Wilkaitis N; Brunt EM; Bacon BR
    Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response.
    Imai Y; Kasahara A; Tanaka H; Okanoue T; Hiramatsu N; Tsubouchi H; Yoshioka K; Kawata S; Tanaka E; Hino K; Hayashi K; Tamura S; Itoh Y; Sasaki Y; Kiyosawa K; Kakumu S; Okita K; Hayashi N
    J Gastroenterol; 2004 Nov; 39(11):1069-77. PubMed ID: 15580400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.